Skip to main content
Fig. 4 | Journal of Biomedical Science

Fig. 4

From: Neutralizing antibodies targeting a novel epitope on envelope protein exhibited broad protection against flavivirus without risk of disease enhancement

Fig. 4

ADE capacities of JEV-NTE- or DV/ZV-NTE-immune sera in vitro. A–F Comparison of ADE effects in K562 cells by infection (MOI = 0.1) with A JEV, B DENV-1, C DENV-2, D DENV-3, E DENV-4, or F ZIKV in the absence or presence of serial fourfold dilutions of mAb 4G2 (purple symbols), JEV-NTE-immune sera (red symbols), or DV/ZV-NTE-immune sera (blue symbols). Commercially available flavivirus monoclonal antibody mAb 4G2 served as the positive control. The viral titers of infected cells were determined by focus-forming assay. The fold enhancement was defined as the viral titer of infected cells in the presence of sera divided by the viral titer of infected cells in the absence of sera. The data are representative results of two independent experiments. Data are presented as the means ± SD of two independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001 (by Two-way ANOVA)

Back to article page

Journal of Biomedical Science

ISSN: 1423-0127